KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

AbCellera Biologics (ABCL) Other Operating Expenses (2020 - 2026)

AbCellera Biologics filings provide 7 years of Other Operating Expenses readings, the most recent being $938000.0 for Q1 2026.

  • Quarterly Other Operating Expenses rose 1.74% to $938000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $993000.0 through Mar 2026, down 98.66% year-over-year, with the annual reading at $3.8 million for FY2025, 95.19% down from the prior year.
  • Other Operating Expenses hit $938000.0 in Q1 2026 for AbCellera Biologics, up from -$7.8 million in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $49.6 million in Q1 2022 and bottomed at -$7.8 million in Q4 2025.
  • Average Other Operating Expenses over 5 years is $11.1 million, with a median of $6.1 million recorded in 2023.
  • The largest annual shift saw Other Operating Expenses skyrocketed 494.04% in 2024 before it crashed 997.0% in 2025.
  • AbCellera Biologics' Other Operating Expenses stood at $15.3 million in 2022, then tumbled by 148.75% to -$7.5 million in 2023, then soared by 111.61% to $867000.0 in 2024, then crashed by 997.0% to -$7.8 million in 2025, then skyrocketed by 112.06% to $938000.0 in 2026.
  • Per Business Quant, the three most recent readings for ABCL's Other Operating Expenses are $938000.0 (Q1 2026), -$7.8 million (Q4 2025), and $3.9 million (Q3 2025).